Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) Stock Overview
Explore Drugs Made In America Acquisition II Corp. Ordinary Shares’s financial performance, market position, analyst ratings, and future outlook.
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII)
Key Financials
Key Financials
Market Cap
645.9M
P/E Ratio
33.47
EPS (TTM)
$0.14
ROE
0.03%
DMII Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Drugs Made In America Acquisition II Corp. Ordinary Shares's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of DMII on the NASDAQ shows an RSI of 68.51, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $10.29 for the NASDAQ listing.
Key metrics behind Drugs Made In America Acquisition II Corp. Ordinary Shares's NASDAQ-traded stock include a P/E ratio of 33.47 and a market capitalization of 645.9M. Combined with our AI analysis, these give both institutional and retail investors a clear view of DMII on the NASDAQ.